Concourse Financial Group Securities, Inc. Codiak Bio Sciences, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

10 transactions

Quarter	Operation	Price Per share
Q1 2023 May 15, 2023	BUY	$0.18 - $0.81 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$0.32 - $0.9 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$0.82 - $3.19 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$2.24 - $6.96 $0 - $0
Q1 2022 May 09, 2022	BUY	$4.3 - $12.95 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$10.0 - $16.78 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$15.58 - $22.88 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$11.72 - $26.81 $0 - $0
Q1 2021 May 13, 2021	BUY	$13.49 - $31.53 $0 - $0
Q4 2020 Feb 02, 2021	BUY	$7.9 - $32.3 $0 - $0

Others Institutions Holding CDAK

# of Institutions

Shares Held

238K

Call Options Held

Put Options Held

Empery Asset Management, LP New York, NY

238K
Shares

$2,379
1.11% of portfolio

View Full List

About Codiak BioSciences, Inc.

Ticker CDAK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,995,200
Market Cap $360K
Description
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of...

More about CDAK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account